1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
徐杰茹, 陈磊, 张敏, 等. 1990—2019年中国卵巢癌发病与死亡趋势及其年龄-时期-队列模型分析. 中国肿瘤, 2022, 31(4): 276-283.
|
3. |
Perrone AM, Girolimetti G, Procaccini M, et al. Potential for mitochondrial DNA sequencing in the differential diagnosis of gynaecological malignancies. Int J Mol Sci, 2018, 19(7): 2048.
|
4. |
The Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian carcinoma. Nature, 2011, 474: 609-615.
|
5. |
Colombo N, Lorusso D, Scollo P. Impact of recurrence of ovarian cancer on quality of life and outlook for the future. Int J Gynecol Cancer, 2017, 27(6): 1134-1140.
|
6. |
du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, 2009, 115(6): 1234-1244.
|
7. |
Vahidfar N, Farzanefar S, Ahmadzadehfar H, et al. A review of nuclear medicine approaches in the diagnosis and the treatment of gynecological malignancies. Cancers (Basel), 2022, 14(7): 1779.
|
8. |
Slart RHJA, Writing group, Reviewer group, et al. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging, 2018, 45(7): 1250-1269.
|
9. |
Liu S, Feng Z, Wen H, et al. 18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value. Jpn J Radiol, 2018, 36(9): 544-550.
|
10. |
Nawi NM, Mohamad I, Khader M, et al. Diagnostic accuracy of 18F-FDG PET/CT in the evaluation of recurrent ovarian cancer. Bangladesh J Medical Sci, 2021, 20(2): 302-312.
|
11. |
西尔艾力·吾门尔, 赵艳萍. (18)F-FDGPET/CT显像联合CA125及HE4在上皮性卵巢癌患者术后复发/转移诊断中的价值. 分子影像学杂志, 2020, 43(1): 70-75.
|
12. |
Vallius T, Hynninen J, Kemppainen J, et al. 18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. Eur J Nucl Med Mol Imaging, 2018, 45(7): 1224-1232.
|
13. |
Lee YJ, Kim YM, Jung PS, et al. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients. J Gynecol Oncol, 2018, 29(3): e36.
|
14. |
李敏, 李绪清, 颜士杰, 等. (18)F-脱氧葡萄糖PET/CT联合CA125在诊断卵巢癌复发转移中的应用价值. 重庆医科大学学报, 2017, 42(12): 1635-1638.
|
15. |
Kim TH, Kim J, Kang YK, et al. Identification of metabolic biomarkers using serial 18F-FDG PET/CT for prediction of recurrence in advanced epithelial ovarian cancer. Transl Oncol, 2017, 10(3): 297-303.
|
16. |
Ghosh J, Thulkar S, Kumar R, et al. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study. Natl Med J India, 2013, 26(6): 327-331.
|
17. |
Antunovic L, Cimitan M, Borsatti E, et al. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities. Clin Nucl Med, 2012, 37(8): e184-e188.
|
18. |
Chung HH, Kwon HW, Kang KW, et al. PreoperativeFDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. J Gynecol Oncol, 2012, 23(1): 28-34.
|
19. |
奚嘉婧, 兰晓莉, 曹国祥, 等. 18F-FDG PET/CT显像在上皮性卵巢癌术后随访中的应用价值及对临床决策的影响. 中国医学影像技术, 2011, 27(7): 1451-1454.
|
20. |
Nasu K, Abe W, Takai N, et al. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment. Arch Gynecol Obstet, 2011, 283(5): 1121-1126.
|
21. |
García-Velloso MJ, Jurado M, Ceamanos C, et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging, 2007, 34(9): 1396-1405.
|
22. |
Murakami M, Miyamoto T, Iida T, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer, 2006, 16(Suppl 1): 99-107.
|
23. |
万卫星, 尤徐阳, 陆燕君, 等. ~(18)F-FDG符合线路显像在卵巢上皮性癌术后监测中的价值. 中华核医学杂志, 2005, (5): 22-25.
|
24. |
Cho SM, Ha HK, Byun JY, et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol, 2002, 179(2): 391-395.
|
25. |
Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med, 2004, 45(2): 266-271.
|
26. |
Anjos DA, Etchebehere EC, Ramos CD, et al. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med, 2007, 48(5): 764-770.
|
27. |
Nakamoto Y, Saga T, Fujii S. Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer, 2005, 15(5): 701-709.
|
28. |
Sun J, Cui XW, Li YS, et al. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Eur Rev Med Pharmacol Sci, 2020, 24(13): 7276-7283.
|
29. |
Castellucci P, Perrone AM, Picchio M, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun, 2007, 28(8): 589-595.
|
30. |
Yuan Y, Gu ZX, Tao XF, et al. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. Eur J Radiol, 2012, 81(5): 1002-1006.
|
31. |
郭佳, 陈跃. 18F-FDGPET/CT显像监测卵巢癌患者术后复发/转移的临床价值分析. 山东医药, 2011, 51(3): 55-56.
|
32. |
Vargas HA, Burger IA, Goldman DA, et al. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol, 2015, 25(11): 3348-3353.
|
33. |
Yamamoto M, Tsujikawa T, Fujita Y, et al. Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy. Cancer Sci, 2016, 107(4): 478-485.
|
34. |
Bono Y, Mizumoto Y, Nakamura M, et al. FDG-PET-positive ovarian thecoma with GLUT5 expression: five cases. J Obstet Gynaecol Res, 2017, 43(3): 599-603.
|